Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 5/20 | 0.46 |
| ▸ | CCNC | P24863 | 3/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.44 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478426 | 0.83 | CDK8 (0.46) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL16289814 | 0.79 | CDK8 (0.48) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL14178720 | 0.76 | PIK3CA (0.43) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL29843629 | 0.76 | SLC22A12 (0.51) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL633785 | 0.76 | CDK8 (0.48) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL23625624 | 0.76 | CDK8 (0.48) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL29843782 | 0.76 | CDK8 (0.48) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL730084 | 0.76 | PDE5A (0.49) | SLC22A12CDK8CCNCGAKRIPK2 | |
| SCHEMBL981901 | 0.76 | CDK8 (0.51) | SLC22A12CDK8CCNCCCR1CCR5 | |
| SCHEMBL30369707 | 0.76 | PDE5A (0.49) | SLC22A12CDK8CCNCGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015678-A | Fused pyridine active substances as c-Met inhibitors | HOFFMANN LA ROCHE | 2011-04-13 | — | — | CN | disclosed |
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2247584-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009093049-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093049-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | MET, ROS1, ABL1 | SLC22A12 2947/4885CDK8 658/4885CCNC 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.